Vertex Pharmaceuticals Stock Earnings Reports

Vertex reported a strong start to 2026 with Q1 product revenue of $2.99B, up 8% year/year. Growth was broad-based: CF remained the core franchise (AlifTrack continues to gain share and has surpassed $1B cumulative revenue), while newer franchises contributed meaningfully—KASJEVY recorded $43M (now >500 patients in the treatment journey) and GERNAVICS generated $29M (>1M prescriptions written since launch). Management highlighted rapid commercial and regulatory execution and reiterated full-year 2026 revenue guidance of $12.95B–$13.10B (8%–9% growth) and confidence in >$500M revenue from non-CF products. R&D momentum is a key theme: Povitacicept (Povi) delivered highly positive Phase III RAINIER interim results in IgA nephropathy (large reductions in proteinuria, strong secondary endpoints, favorable safety), prompting a rapid BLA submission (27 days from database lock). Povi is advancing in primary membranous nephropathy (Phase III initiated) and a Phase II proof-of-concept in myasthenia gravis is underway. Enaxaplin (AMKD) and VX-407 (ADPKD) programs are progressing; AMPLIFIED enrollment completed and AMPLITUDE interim analysis is expected in early 2027. CF pipeline: label expansions for AlifTrack and TRIKAFTA broaden eligible populations (~95% of CF patients); next-gen CFTR program VX-828 results expected H2 2026. Vertex discontinued the VX-522 mRNA program due to tolerability (lung inflammatory) issues and will reassess delivery approaches for patients with no CFTR protein. Financials: non-GAAP operating income and EPS grew; ended Q1 with ~$13B cash; share repurchases continued. Management emphasized building a fourth commercial franchise in renal disease, readiness to launch Povi if approved, and continued investment in late-stage programs and commercial infrastructure.